Preventing recurrence and progression in superficial bladder cancer

Current Opinion in Urology

Volumn 6, Issue 5, 1996, Pages 272-275

  Newling, Donald W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; ALPHA2 INTERFERON; BCG VACCINE; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; IMMUNOMODULATING AGENT; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN; MITOXANTRONE; PYRIDOXINE; THIOTEPA;

BLADDER CANCER; BONE MARROW TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CHEMICAL CYSTITIS; CYSTECTOMY; HUMAN; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; LACTOBACILLUS CASEI; MILIARY TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

EID: 0029801304     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199609000-00009     Document Type: Short Survey

References (25)

1. Namasivayam S, Whelan P: Intravesical mitozantrone in recurrent • superficial bladder cancer: a phase II study. Br J Urol 1995, 75:740-743. The first description of phase II results with a new active intravesical agent.
2. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, •• Groshen S, Lieskovsky G, Boyd SD, Skinner DG: Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1996, 76:833-839. A good assessment of the prognostic factors, which may dictate the need for early radical surgery.
3. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of •• current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transition cell carcinoma of the bladder. J Urol 1995, 53:1444-1450. This retrospective analysis of many studies of intravesical chemotherapy shows that, currently, no agent has influenced the rate of progression in superficial bladder cancer.
4. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S, and the BLP •• Study Group: Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995, 27:104-109. First prospective randomized study of Lactobacillus casei showing a significant effect of this agent.
5. Sarovsky MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA: Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992, 147:31-33.
6. Lamm DL, Van der Meijden APM, Akaza H: Chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995, 2(suppl 2):23-33.
7. Traynelis CL, Lamm DL: Current status of intravesical therapy for bladder cancer. In Urology Annual. Edited by Ruysch S. New York, WW North & Co.; 1994:113-143.
8. Kurth KH, Schröder FH, Senge T, De Bruyne FMJ, Carpentier PJ, Riedl H, Sylvester R, de Paul M and members of the EORTC GU-Group: Adjuvant therapy of superficial transitional cell carcinoma - an EORTC randomized trial comparing doxorubicin, ethoglucid and TUR alone. In Superficial Bladder Tumours. Edited by Schröder FH, Ricards B. New York: Alan R. Liss, 1985: 135-142.
9. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 1995, 153:1444-1450.
10. Oosterlinck W, Kurth KH, Schröder FH, Bultinck J, Hammond B, Sylvester R, and members of the EORTC GU-Group. An EORTC GU-Group randomized trial comparing TUR followed by a single instillation of epirublcln or water in single stage Ta T1 carcinoma of the bladder. J Urol 1993, 149:749-752.
11. Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, et al.: The Japanese Urological Cancer Research Group for Adriamycin. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 1987, Suppl 20:91-96.
12. Bouffioux, Kurth KH, Bono A, Oosterlinck C, Boeken Kruger W, de Paul M, Sylvester R, and the members of the EORTC GU-Group: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 EORTC randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short term versus long term treatment J Urol 1995, 153:934-941.
13. Morales A, Eidinger, Bruce AW: Intracavitary BCG in the treatment of superficial bladder tumours. J Urol 1976, 116:18-23.
14. Lamm DL. BCG in perspective: advances in the treatment of •• superficial bladder cancer. Eur Urol 1995, 27(suppl 1):2-8. A useful update of a knowledge of BCG therapy, including the question of maintenance dosing.
15. Prior K, Goddard J, Goldstein D, Strikker P, Russel P, Golovsky D, Penny R: BCG enhances monocyte and lymphocyte controlled bladder tumour cell killing. Br J Cancer 1995, 71:801-807.
16. Vegt PDJ, Witjes A, Witjes WPT, Witjes JE, Witjes WPJ, Doesburg WH, DeBruyne FMJ, Van der Meyden EPM: A randomized study of intravesical MMC, BCG Tice and BCG RIVM treatment in Ta, T1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995, 153:929-933.
17. Van der Meijden APM: Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995, 27(suppl 1):23-28.
18. Mack D, Fnck J: Low dose BCG therapy in superficial high risk bladder cancer: a phase II study with BCG strain Connaught Canada. Br J Urol 1995, 75:185-187.
19. Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995, 27(suppl 1):19-22.
20. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore jr. •• WF, Oettgen HF: Intravesical BCG therapy prevents tumour progression and death from superficial bladder cancer: ten year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408. An important study showing quite clearly that BCG influences the rate of progression in superficial bladder cancer.
21. Kalbe T, Boer M, Staehler G: Intravesical prophylaxis with BCG versus interferon α for superficial bladder cancer [Abstract]. J Urol 1994, 151:233.
22. Jarinciu CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder with KLH - a randomized study. J Urol 1988, 139:723-726.
23. Newling DWW, Robinson MRG, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R, and members of the EORTC GU-Group: Trypthophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective randomized phase III study performed by the EORTC GU-Group. Eur Urol 1995, 27:110-116.
24. Byar D, Blackhard C: Comparison of pyridoxine, placebo and topical thlotepa in presenting recurrence of stage I bladder carcinoma. Urology 1977, 10:556-560.
25. Van der Meijden APM, Hall RR, Pavone Maculuso M, Pawinsky A, Sylvester R, Van Glabbeke M: Marker tumour response to the sequential combination of intravesical therapy with MMC and BCG-RIVM in multiple superficial bladder tumours. Eur Urol 1996, 29:199-203.